

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

### ***APPLICATION NUMBER:***

**219474Orig1s000**

***Trade Name:*** Adquey ointment,1%

***Generic or Proper Name:*** difamilast

***Sponsor:*** Acrotech Biopharma Inc.

***Approval Date:*** February 12, 2026

***Indication:*** For the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis.

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 219474Orig1s000

### CONTENTS

|                                                           |
|-----------------------------------------------------------|
| <b>Reviews / Information Included in this NDA Review.</b> |
|-----------------------------------------------------------|

|                                                                                                                                                                                                   |          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| <b>Approval Letter</b>                                                                                                                                                                            | <b>X</b> |
| <b>Other Action Letters</b>                                                                                                                                                                       |          |
| <b>Labeling</b>                                                                                                                                                                                   | <b>X</b> |
| <b>REMS</b>                                                                                                                                                                                       |          |
| <b>Officer/Employee List</b>                                                                                                                                                                      | <b>X</b> |
| <b>Multidiscipline Review(s)</b> <ul style="list-style-type: none"><li>• Summary Review</li><li>• Clinical</li><li>• Non-Clinical</li><li>• Statistical</li><li>• Clinical Pharmacology</li></ul> | <b>X</b> |
| <b>Product Quality Review(s)</b>                                                                                                                                                                  | <b>X</b> |
| <b>Clinical Microbiology / Virology Review(s)</b>                                                                                                                                                 |          |
| <b>Other Reviews</b>                                                                                                                                                                              | <b>X</b> |
| <b>Risk Assessment and Risk Mitigation Review(s)</b>                                                                                                                                              | <b>X</b> |
| <b>Proprietary Name Review(s)</b>                                                                                                                                                                 | <b>X</b> |
| <b>Administrative/Correspondence Document(s)</b>                                                                                                                                                  | <b>X</b> |

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

***APPLICATION NUMBER:***

**219474Orig1s000**

**APPROVAL LETTER**



NDA 219474

## NDA APPROVAL

Acrotech Biopharma Inc.  
Attention: Ashish Anvekar  
President  
279 Princeton Hightstown Road  
East Windsor, NJ 08520

Dear Ashish Anvekar:

Please refer to your new drug application (NDA) received February 13, 2025, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Adquey (difamilast) ointment, 1%.

This NDA provides for the use of Adquey (difamilast) ointment, 1% for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, and Patient Package Insert) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

## **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 219474**” Approval of this submission by FDA is not required before the labeling is used.

## **DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for Adquey (difamilast) ointment, shall be 36-months from the date of manufacture for 27g and 85g fill tube, and 18-months for the 3g physician sample tubes, when stored at 20°C to 25°C (68°F to 77°F) and excursions permitted to 15°C to 30°C (59°F to 86°F).

## **ADVISORY COMMITTEE**

Your application for Adquey (difamilast) ointment, 1% was not referred to an FDA advisory committee because outside expertise was not necessary; there were no issues that would benefit from advisory committee discussion.

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to 3 months because necessary studies are impossible or highly impractical. This is because atopic dermatitis is rare in this population.

We are deferring submission of your pediatric study for ages 3 months to less than 2 years for this application because this product is ready for approval for use in adults and pediatric patients 2 years of age and older; however, pediatric study for ages 3 months to 2 years have not been completed.

Your deferred pediatric study required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act is required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 314.81 and section 505B(a)(4)(C) of the Federal Food, Drug, and Cosmetic Act. This required study is listed below.

- 4963-1 Conduct an adequate and well-controlled trial in the United States in subjects ages 3 months to <2 years with mild to moderate atopic dermatitis. Evaluate the safety and pharmacokinetics of difamilast under maximal use conditions in an adequate number of subjects with disease at the upper range of severity.

Final Protocol Submission: 06/2026

Study Completion: 01/2029

Final Report Submission: 06/2029

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.<sup>3</sup>

Submit the protocol(s) to your IND 112973 with a cross-reference letter to this NDA. Reports of this required pediatric postmarketing study must be submitted as an NDA or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from this study. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>4</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>5</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>6</sup>

---

<sup>3</sup> See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act* (October 2019).

<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>4</sup> For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>6</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

## **COMPENDIAL STANDARDS**

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website<sup>7</sup>.

If you have any questions, contact Craig Johnson, Regulatory Project Manager, at 301-796-3921 or [Craig.Johnson@FDA.HHS.Gov](mailto:Craig.Johnson@FDA.HHS.Gov).

Sincerely,

*{See appended electronic signature page}*

Nikolay P. Nikolov, MD,  
Director,  
Office of Immunology and Inflammation  
Office of New Drugs  
Center for Drug Evaluation and Research

### **ENCLOSURE(S):**

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert or Medication Guide
- Carton and Container Labeling

---

<sup>7</sup> <https://www.uspnf.com/>

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

NIKOLAY P NIKOLOV  
02/12/2026 12:07:06 PM